About Goldline Pharmaceutical Limited
Data last updated:
Goldline Pharmaceutical Limited is a public limited company based in Nagpur, Maharashtra, India. It operates in the pharmaceutical retail and distribution segment of the pharmaceuticals sector. It was incorporated on 02 August 2004 and has been in existence for over 22 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U51397MH2004PLC147806. Its GSTIN is 27AACCG2989F1ZE (Maharashtra). The company holds 2 GST registrations, of which 1 is active.
The company has an authorised share capital of ₹13.5 Cr and a paid-up capital of ₹8.71 Cr. It was formerly known as Goldline Pharmaceutical Private Limited. It is led by directors including Amol Laxmikant Mujumdar (Managing Director) and Swapan Khandelwal (Whole-Time Director).
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Nagpur, Maharashtra.
As per the financials filed for FY 2025, the company reported a revenue of ₹28.06 Cr, a growth of 19% compared to the previous year. For the same year it recorded a net profit of ₹2.83 Cr (net margin 10.1%) and EBITDA of ₹5.83 Cr (EBITDA margin 20.8%). Revenue has declined at a compounded annual rate (CAGR) of 5% over three years and 1% over five years.
The company has about 85 employees on its provident fund (EPFO) records.
As per MCA filings, the company has open charges of ₹8.54 Cr and satisfied charges of ₹3.53 Cr on record. Court records list 3 cases involving the company, including 2 filed against it; 1 case is pending. The company has 24 deals on record (23 market trades, 1 ipo); the latest was in September 2026. Its 10 peer companies in the Pharma industry (Pharma Retail and Distribution) are compared by revenue, 5 larger and 5 smaller; the largest is Medi Wings Bio Science Private Limited with revenue of ₹28.19 Cr.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website goldlinepharma.in.
- EmailLocked
- TelephoneLocked
- Website
- Social MediaLocked
- Registered Address103 F – 1 Leelaapartmentshilpahsgsociety Nearsaptagirinagar Shanidham Narend, Ra Nagar, Nagpur, Maharashtra, India – 440015
- IndustryPharma, Pharmaceutical Retailers & Distributors
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Business Activity of Goldline Pharmaceutical Limited
The main business activity of Goldline Pharmaceutical is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | Locked |
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Goldline Pharmaceutical Limited FY 2025 filings available
Goldline Pharmaceutical Limited reported revenue of ₹28.06 Cr (up 19% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR) of Goldline Pharmaceutical Limited
Revenue rose 19% in the latest year, though over five years it has declined at a compounded annual rate (CAGR) of 1%. EBITDA rose 32% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary of Goldline Pharmaceutical Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | •••• | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• | •••• |
| Total Revenue | •••• | •••• | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• | •••• |
| EBITDA | ₹5.83 Cr | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• | •••• | •••• |
| Net Profit (PAT) | ₹2.83 Cr | •••• | •••• | •••• | •••• |
| Balance Sheet | |||||
| Share Capital | •••• | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• | •••• |
Financial Ratios of Goldline Pharmaceutical Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 20.8% | •••• | •••• | •••• | •••• |
| Net Profit Margin | 10.1% | •••• | •••• | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• | •••• | •••• |
| Liquidity and Debt | |||||
| Current Ratio | •••• | •••• | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• | •••• | •••• |
| Efficiency and Growth | |||||
| Asset Turnover | •••• | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Goldline Pharmaceutical are in the company report.
Financial statements from 2015
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Peer Comparison of Goldline Pharmaceutical Limited
Goldline Pharmaceutical Limited is compared with the companies closest to it by revenue in the Pharma industry (Pharma Retail and Distribution). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Medi Wings Bio Science Private Limited | ₹28.19 Cr (FY 2025) | •••• | •••• | 10.0% | •••• | Bangalore, Karnataka, India |
| Akola Life Support Private Limited | ₹28.09 Cr (FY 2025) | •••• | •••• | 11.0% | •••• | Akola, Maharashtra, India |
| Guru Nanak Medicos Private Limited | ₹28.08 Cr (FY 2025) | •••• | •••• | 11.0% | •••• | Chandigarh, India |
| Canvarzys Healthcare Limited | ₹28.08 Cr (FY 2025) | •••• | •••• | 4.0% | •••• | Ludhiana, Punjab, India |
| Tara Medicos Wellness Private Limited | ₹28.06 Cr (FY 2025) | •••• | •••• | 3.0% | •••• | Jaipur, Rajasthan, India |
| Goldline Pharmaceutical Limited this company | ₹28.06 Cr (FY 2025) | •••• | •••• | 19.0% | •••• | Nagpur, Maharashtra, India |
| Excelcare Health Alliance Private Limited | ₹28.04 Cr (FY 2025) | •••• | •••• | -1.0% | •••• | Bangalore, Karnataka, India |
| Ketki Research Institute of Medical Sciences Ltd | ₹28.02 Cr (FY 2025) | •••• | •••• | 10.0% | •••• | Nagpur, Maharashtra, India |
| RST Healthcare Private Limited | ₹28.02 Cr (FY 2025) | •••• | •••• | 11.0% | •••• | Patna, Bihar, India |
| Sainath Agencies (Pharma) Private Limited | ₹27.9 Cr (FY 2023) | •••• | •••• | -43.0% | •••• | Mumbai, Maharashtra, India |
| Apollo Medi-Services Pvt. Ltd. | ₹27.89 Cr (FY 2024) | •••• | •••• | 32.0% | •••• | Kolkata, West Bengal, India |
Peers are the five companies nearest above and the five nearest below Goldline Pharmaceutical by revenue in the Pharma industry (Pharma Retail and Distribution), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Auditor Details of Goldline Pharmaceutical Limited
Goldline Pharmaceutical Limited is audited by SHAH & RAUT for the financial year 2023.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| SHAH & RAUT | Locked | Locked | Locked |
Complete auditor history
Appointment and cessation dates and past auditor changes are in the company report.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Board of Directors of Goldline Pharmaceutical Limited
Goldline Pharmaceutical has 8 current directors and 5 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Swapan Khandelwal Also directs: Cherry Voyaging Private Limited, Activista Healthcare Private Limited, Nucleage Lifesciences Private Limited and 4 more | Whole-Time Director | 11 Apr 2011 | 15 Years 6 Months | Current |
| Amol Laxmikant Mujumdar Also directs: Cherry Voyaging Private Limited | Managing Director | 02 Aug 2004 | 22 Years 2 Months | Current |
| Mehul Hari Ranade Also directs: Mumukshu Management Services LLP, Jiya Eco-Products Limited, Asud Renewables Private Limited and 1 more | Director | 30 Sep 2024 | 2 Years 0 Months | Current |
| Prashant Shrikrishna Karkare | Director | 16 Jul 2013 | 13 Years 2 Months | Current |
| Renuka Saurabh Borole Also directs: Jiya Eco-Products Limited, Dra Consultants Limited | Director | 30 Sep 2024 | 2 Years 0 Months | Current |
| Shraddha Kiran Kulkarni | Director | 17 Oct 2024 | 1 Years 11 Months | Current |
Ownership and Shareholding of Goldline Pharmaceutical Limited
Shareholding and ownership data
Promoter, institutional, public and beneficial ownership figures are in the company report.
- Ownership categories
- Historical changes
- Group structure
- FII and DII holdings
Verified entity values are shown only after access is granted.
Charges & Borrowings of Goldline Pharmaceutical Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 12 Dec 2024 | Others | ₹42.1 Lakh | Open |
| 02 May 2022 | Bank of India | ₹46 Lakh | Open |
| 16 Jan 2013 | Bank of India | ₹7.65 Cr | Open |
| 27 Dec 2013 | Bank of India | ₹8 Lakh | Satisfied |
| 17 Feb 2011 | State Bank of India | ₹3.45 Cr | Satisfied |
Total charge records: 5 View all charges
Deals & Funding of Goldline Pharmaceutical Limited
Goldline Pharmaceutical Limited has 24 deals on record (23 market trades, 1 ipo); the latest was in September 2026.
Deals on record (5 of 24)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Aug 2026 | Market trade | ₹83 Lakh | Buyer: 3 individuals Seller: Cumulative Capital Private Limited , 2 individuals |
| Aug 2026 | Market trade | ₹19.8 Lakh | Buyer: Cumulative Capital Private Limited Seller: Upsurge Opportunities Fund 1 |
| Aug 2026 | Market trade | ₹71.3 Lakh | Buyer: Samurai Securities Private Limited , an individual Seller: Upsurge Opportunities Fund 1, Samurai Securities Private Limited , an individual |
| Jul 2026 | Market trade | ₹98.4 Lakh | Buyer: 2 individuals Seller: Amjay Impex Private Limited , 2 individuals |
| Jul 2026 | Market trade | ₹63.4 Lakh | Buyer: Amjay Impex Private Limited Seller: an individual |
Full deal history
All 24 deals with amounts, valuations, instruments and every party are in the company report.
- Every funding round and share transfer
- Amounts and valuations
- Investors, buyers and sellers
- Instruments and deal dates
Verified entity values are shown only after access is granted.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal Cases of Goldline Pharmaceutical Limited
Goldline Pharmaceutical Limited has 3 court cases on record: 2 filed against it, 1 where it is another party. 1 case is pending and 2 are disposed. Status as checked between 02 Oct 2026 and 04 Oct 2026.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 3 | 2 | 1 |
Cases on record (3 of 3)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Sawai Madhopur, Rajasthan | Criminal case | Company is another party | Pending |
| District court, Ahmedabad, Gujarat | Court case (CR EN) | Filed against the company by an individual | Disposed |
| District court, Ahmedabad, Gujarat | Criminal complaint | Filed against the company by an individual | Disposed |
Full case history
All 3 cases with case numbers, court, year-wise trend, opposite parties and decision dates are in the company report.
- Every case with its case number
- Year-wise trend
- Opposite parties
- Decision dates and orders
Verified entity values are shown only after access is granted.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Employees and EPFO Compliance at Goldline Pharmaceutical Limited
Goldline Pharmaceutical Limited has a workforce of 85 employees as of Apr 07, 2024.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
CIN History of Goldline Pharmaceutical Limited
Goldline Pharmaceutical has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is U51397MH2004PLC147806, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U51397MH2004PLC147806 | Current |
| U51397MH2004PTC147806 | Previous |
| L51397MH2004PLC147806 | Previous |
Recent Activity on Goldline Pharmaceutical Limited
Goldline Pharmaceutical Limited has 13 board changes on record since 2004: 8 appointments and 5 cessations. The latest: Shraddha Kiran Kulkarni ceased to be Additional Director on 29 Sep 2025.
12 earlier events are listed in the company report.
Credit Ratings, Litigation & Regulatory Alerts for Goldline Pharmaceutical Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Goldline Pharmaceutical Limited
MSME payment history
Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Goldline Pharmaceutical Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Goldline Pharmaceutical Limited
Goldline Pharmaceutical has 2 GST registrations: 1 active and 1 cancelled or inactive.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AACCG2989F1ZE | Maharashtra | Active | 01 Jul 2017 |
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Goldline Pharmaceutical Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Goldline Pharmaceutical Limited
Goldline Pharmaceutical is an active public limited company based in Nagpur, Maharashtra, India. The company works in pharmaceutical retailers and distributors, within the pharma industry. It was incorporated on 02 August 2004 (22+ years old) and is registered under CIN U51397MH2004PLC147806.
Goldline Pharmaceutical reported revenue of ₹28.06 Cr for FY 2025 (up 19% YoY).
Goldline Pharmaceutical has 8 current directors:
- Amol Laxmikant Mujumdar - Managing Director
- Swapan Khandelwal - Whole-Time Director
- Mehul Hari Ranade - Director
- Prashant Shrikrishna Karkare - Director
- Renuka Saurabh Borole - Director
- Shraddha Kiran Kulkarni - Director
- Prashant Vithalrao Rahate - Director
- Avinash Pandurang Ambulkar - Director
Goldline Pharmaceutical reported a net profit of ₹2.83 Cr (net margin 10.1%) and EBITDA of ₹5.83 Cr (EBITDA margin 20.8%) for FY 2025, as per its filed financial statements.
The compounded annual growth rate (CAGR) of the revenue of Goldline Pharmaceutical is 5% over three years and -1% over five years. In the latest year (FY 2025) revenue rose 19%. CAGR is the steady yearly rate that links the first and the last year.
The GSTIN of Goldline Pharmaceutical is 27AACCG2989F1ZE, registered in Maharashtra. The company has 2 GST registrations in all, of which 1 is active and 1 is cancelled or inactive.
The CIN (Corporate Identification Number) of Goldline Pharmaceutical is U51397MH2004PLC147806. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Goldline Pharmaceutical has 3 court cases on record: 2 filed against it. 1 is pending.
Goldline Pharmaceutical was incorporated on 02 August 2004, making it 22+ years old. It is registered with the Registrar of Companies, Mumbai.
Goldline Pharmaceutical has 24 deals on record (23 market trades, 1 ipo); the latest was in September 2026.
The peers of Goldline Pharmaceutical by revenue are Medi Wings Bio Science Private Limited, Akola Life Support Private Limited, Guru Nanak Medicos Private Limited, Canvarzys Healthcare Limited, Tara Medicos Wellness Private Limited and 5 more, all in the Pharma industry (Pharma Retail and Distribution).